Genetic Diseases

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA withdrawal · 2018-02-16
EMA Application withdrawn: Infinia (alpha-1-antitrypsin) — Kamada BioPharma Limited at Fieldfisher LLP
The EMA application for Infinia (alpha-1-antitrypsin) by Kamada BioPharma Limited at Fieldfisher LLP was withdrawn.